In ptns with IgA nephropathy (IgANp), im/m therapy is generally preserved for ptns who’re at higher risk for disease progress.
Macrophage
infiltration &
the response to im/m therapy in IgA nephropathy (Dec 2021)
Abbreviations:
o
IgANp: IgA nephropathy.
o
im/m: immunosuppressive/immunosuppression
o
ttt: treatment
o
mo: months
In ptns with IgA nephropathy (IgANp), im/m
therapy is generally preserved for ptns who’re at higher risk for disease
progress; however, tools recognizing which ptns are likely to benefit from therapy
are currently deficient.
Study:
almost more than 600 Chinese ptns with IgANp at higher risk for disease progress and
had received im/m
therapy for an average of 18
mo., increased levels of macrophage infiltration within glomeruli on renal
biopsy were mostly associated with a markedly higher probability of a better response
to im/m therapy
in comparison with lowered levels.
The recently given data (i.e., the magnitude
of macrophage infiltrative intensity) if combined with associated clinical and
histological data may be precisely help in prediction of the response to im/m. therapy. However, meanwhile these data
may help identifying ptns who may benefit from im/m
therapy, more validated evidence in other ptns cohorts is currently warranted.
References
§ Intensity of Macrophage
Infiltration in Glomeruli Predicts Response to Immunosuppressive Therapy in
Patients with IgA Nephropathy. Xie D, Zhao H, Xu X, Zhou Z, Su C, Jia N, Liu Y,
Hou FF. J Am Soc Nephrol. 2021;
COMMENTS